DUBLIN--(http://www.researchandmarkets.com/research/sn7nsz/psoriasis_event) has announced the addition of Decision Resources, Inc's new report "Psoriasis (Event Driven)" to their offering.)--Research and Markets (
Despite the major impact psoriasis has on patients' quality of life, physicians believe many patients are untreated or undertreated, offering important commercial opportunities for current and emerging agents targeting this indication. During our ten-year forecast period, intense competition between the TNF-a inhibitors etanercept and adalimumab and the interleukin inhibitor ustekinumab has the potential to transform current treatment algorithms and define new market leaders. These current therapies will vie for share with several emerging agents with novel mechanisms of action and distinct risk-benefit profiles.
Key Topics Covered:
What are the key parameters of the psoriasis market?
What factors are driving the market for psoriasis therapies?
What factors are constraining the market for psoriasis therapies?
What are the drug development activities of note in psoriasis?
What do the experts say?
What key challenges and opportunities remain?
1 Etiology and Pathophysiology
2 Epidemiology and Patient Populations
3 Current Therapies and Medical Practice
4 Unmet Needs
5 Emerging Therapies
6 Market Outlook
Tables and Figures
For more information visit http://www.researchandmarkets.com/research/sn7nsz/psoriasis_event
Source: Decision Resources, Inc